Liangbo Shen, MD, discussed unmet needs in geographic atrophy and how implants could ease treatment burden.
News|Articles|July 21, 2026
Retina World Congress 2026 recap: Durability, diagnosis, discovery, and what’s next in retina care
Author(s)Eye Care Network Staff
Fact checked by: Afton Woodward
Presenters highlight clinical insights and lessons from recent trial data and surgical experience
Advertisement
Advertisement
On efficacy, Regillo said PDS “clearly outperforms” real-world anti-VEGF biologic injections over an extended time frame, with patients maintaining vision gains through the maintenance phase. On safety, most adverse events occurred around the time of surgery and became less frequent over time. “It’s comforting to know that we have 7 years of follow-up that we can tell patients what to expect having this device,” he said.
Related to this article
Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.
Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point and beat the dexamethasone implant on visual and anatomic measures at 24 weeks.
Timothy M. Janetos, MD, Donald J. D’Amico, MD, and Mark J. Gallardo, MD, point to uveitis access, clinical trial rigor, and procedural pharmaceuticals.
FDA accepts vamikibart BLA for UME as data show sustained gains at 1 year; decision July 2027.
Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.
Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.
The evidence for nutrition in eye care is strong for some conditions and thin or absent for others.
Advertisement
Advertisement